UmanDiagnostics has of July 1st been acquired by Quanterix Corp
(2019-06-27) We are really proud to become an important part of Quanterix Corp. The merger between the companies hold great promise to truly unlocking the value of NF-L. We are compelled by Quanterix’ vision, mission, and strategy for disrupting the field of neurodegeneration research and diagnostics and are confident in the management team’s ability to continue its superb execution against this substantial opportunity.
Exciting new Alzheimer’s research
(2019-01-23) The NF-L protein as a biomarker has been shown to be predictive of Alzheimer’s disease up to 16 years before onset of symptoms.
Power Precision Health Summit 2018
(2018-12-07) We are proud to announce that our collaborator Quanterix® will be hosting their first Power Precision Health summit in Amsterdam, December 12. Key opinion leaders will sit down with panelists and discuss the implications of their latest innovative research on biomarkers for neurodegeneration, the value of multiplexing and detecting ultra low concentration of cytokines to understand health and disease. Please join us there.
Sweden’s Super Company 2018
(2018-10-16) UmanDiagnostics has been awarded the prestigious nomination Super Company 2018 by the business magazine Veckans Affärer together with Bisnode. Growth and profitability for four years in a row are some of the essential criteria assessed for qualifying on the list. Super Companies accounts for 0.16% of the total number of limited companies in Sweden and is a great proof of UmanDiagnostics business strategy.
Meet us at ECTRIMS Berlin
(2018-09-06) UmanDiagnostics will attend this year ECTRIMS conference in Berlin (October 10-12th). Please visit us at booth no. D06.
UmanDiagnostics recieves ISO13485:2016 certification
(2018-07-06) UmanDiagnostics has today been quality certified according to ISO13485:2016 further strengthening the company commitment to delivering first class products to it’s valued world wide customers.
UmanDiagnostics and Quanterix improving brain injury diagnostics
(2016-11-21) UmanDiagnostics has today entered into a strategic partnership with Quanterix™, a Boston based company digitizing biomarker analysis for precision health. The aim is to further develop UmanDiagnostics NF-light® ELISA to enable blood analysis of traumatic brain injuries and neurodegenerative diseases. Combining superior antibodies with the most sensitive technology has the possibility to transform neurological diagnostics.
UmanDiagnostics starts selling reagents
(2016-10-07) Due to the great interest in using our antibodies on ultra sensitive platforms we are very happy to announce that we now will be able to deliver antibodies and antigen for Neurofilament light detection. Please use our contact form if you need more information.
UmanDiagnostics nominated for award